Anticancer drugs: Crystal-clear targets?

Abstract

ABL http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?db=gene&c md=Retrieve&dopt=full_ report&list_uids=25 The identification of mutations in the epidermal growth factor receptor (EGFR) that account for a subset of patients with non-small-cell lung cancer (NSCLC) prompted the development of several EGFR-targeted tyrosine kinase inhibitors (TKIs). Despite their… (More)
DOI: 10.1038/nrd2321

Topics

  • Presentations referencing similar topics